p53 acetylated by p300 was viewed as an apoptotic marker; however, Skp2 suppresses p53-dependent apoptosis by interrupting interaction between p53 and p300, thereby perturbing p300-mediated p53 acetylation and apoptosis, which makes Skp2 a potential molecular target for cancer therapy [102]. The gene discussed is SKP2; the disease is cancer.